MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects
Pharmaceutics · 11.06.2024 · 16 (6) · 793
DOI: 10.3390/pharmaceutics16060793 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 11.06.2024. Verfasst von Li-Er Deng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Dongguan Traditional Chinese Medicine Hospital, Dongguan 523000, China. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 158 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Scientific Research Project of Colleges and Universities of Education Department of Guangdong Province, Dongguan Social Development Science and Technology Project, Guangdong Medical University Research Project.
Abstract (Originalsprache)
Kidney diseases are important diseases that affect human health worldwide. According to the 2020 World Health Organization (WHO) report, kidney diseases have become the top 10 causes of death. Strengthening the prevention, primary diagnosis, and action of kidney-related diseases is of great significance in maintaining human health and improving the quality of life. It is increasingly challenging to address clinical needs with the present technologies for diagnosing and treating renal illness. Fortunately, metal-organic frameworks (MOFs) have shown great promise in the diagnosis and treatment of kidney diseases. This review summarizes the research progress of MOFs in the diagnosis and treatment of renal disease in recent years. Firstly, we introduce the basic structure and properties of MOFs. Secondly, we focus on the utilization of MOFs in the diagnosis and treatment of kidney diseases. In the diagnosis of kidney disease, MOFs are usually designed as biosensors to detect biomarkers related to kidney disease. In the treatment of kidney disease, MOFs can not only be used as an effective adsorbent for uremic toxins during hemodialysis but also as a precise treatment of intelligent drug delivery carriers. They can also be combined with nano-chelation technology to solve the problem of the imbalance of trace elements in kidney disease. Finally, we describe the current challenges and prospects of MOFs in the diagnosis and treatment of kidney diseases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, Dongguan Traditional Chinese Medicine Hospital, Dongguan 523000, China.
- Dongguan Key Laboratory of Drug Design and Formulation Technology, Guangdong Provincial Key Laboratory of Medical Molecular Diagnostics, Guangdong Medical University, Dongguan 523808, China.
- School of Materials and Environmental Engineering, Shenzhen Polytechnic University, Shenzhen 518055, China.
- Materials Electrochemistry Laboratory, Department of Chemistry, SRM Institute of Science and Technology, Kattankulathur 603 203, Tamil Nadu, India.
ORCID-Profile: Ying Pan, Govindhan Maduraiveeran, Jianqiang Liu
Förderung
- Key Scientific Research Project of Colleges and Universities of Education Department of Guangdong Province
- Dongguan Social Development Science and Technology Project
- Guangdong Medical University Research Project
- Songshan Lake Materials Laboratory
- Guangdong Basic and Applied Basic Research Foundation
- Featured Innovation Project of Guangdong Province
- Special Project in Key Areas of Guangdong Province
Zitieren
APA
Deng, L. E., Guo, M., Deng, Y., Pan, Y., Wang, X., Maduraiveeran, G., Liu, J., & Lu, C. (2024). MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects. Pharmaceutics, 16(6), 793. https://doi.org/10.3390/pharmaceutics16060793
Vancouver
Deng LE, Guo M, Deng Y, Pan Y, Wang X, Maduraiveeran G, et al. MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects. Pharmaceutics. 2024;16(6):793. doi:10.3390/pharmaceutics16060793
BibTeX
@article{Deng2024,
author = {Deng, Li-Er and Guo, Manli and Deng, Yijun and Pan, Ying and Wang, Xiaoxiong and Maduraiveeran, Govindhan and Liu, Jianqiang and Lu, Chengyu},
title = {MOF-Based Platform for Kidney Diseases: Advances, Challenges, and Prospects},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {6},
pages = {793},
doi = {10.3390/pharmaceutics16060793}
}
EUVIMED